These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 25855300)

  • 1. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
    Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
    Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
    Schoofs T; Klein F; Braunschweig M; Kreider EF; Feldmann A; Nogueira L; Oliveira T; Lorenzi JC; Parrish EH; Learn GH; West AP; Bjorkman PJ; Schlesinger SJ; Seaman MS; Czartoski J; McElrath MJ; Pfeifer N; Hahn BH; Caskey M; Nussenzweig MC
    Science; 2016 May; 352(6288):997-1001. PubMed ID: 27199429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
    Scheid JF; Horwitz JA; Bar-On Y; Kreider EF; Lu CL; Lorenzi JC; Feldmann A; Braunschweig M; Nogueira L; Oliveira T; Shimeliovich I; Patel R; Burke L; Cohen YZ; Hadrigan S; Settler A; Witmer-Pack M; West AP; Juelg B; Keler T; Hawthorne T; Zingman B; Gulick RM; Pfeifer N; Learn GH; Seaman MS; Bjorkman PJ; Klein F; Schlesinger SJ; Walker BD; Hahn BH; Nussenzweig MC; Caskey M
    Nature; 2016 Jul; 535(7613):556-60. PubMed ID: 27338952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
    Mendoza P; Gruell H; Nogueira L; Pai JA; Butler AL; Millard K; Lehmann C; Suárez I; Oliveira TY; Lorenzi JCC; Cohen YZ; Wyen C; Kümmerle T; Karagounis T; Lu CL; Handl L; Unson-O'Brien C; Patel R; Ruping C; Schlotz M; Witmer-Pack M; Shimeliovich I; Kremer G; Thomas E; Seaton KE; Horowitz J; West AP; Bjorkman PJ; Tomaras GD; Gulick RM; Pfeifer N; Fätkenheuer G; Seaman MS; Klein F; Caskey M; Nussenzweig MC
    Nature; 2018 Sep; 561(7724):479-484. PubMed ID: 30258136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination anti-HIV antibodies provide sustained virological suppression.
    Sneller MC; Blazkova J; Justement JS; Shi V; Kennedy BD; Gittens K; Tolstenko J; McCormack G; Whitehead EJ; Schneck RF; Proschan MA; Benko E; Kovacs C; Oguz C; Seaman MS; Caskey M; Nussenzweig MC; Fauci AS; Moir S; Chun TW
    Nature; 2022 Jun; 606(7913):375-381. PubMed ID: 35650437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.
    Shingai M; Nishimura Y; Klein F; Mouquet H; Donau OK; Plishka R; Buckler-White A; Seaman M; Piatak M; Lifson JD; Dimitrov DS; Nussenzweig MC; Martin MA
    Nature; 2013 Nov; 503(7475):277-80. PubMed ID: 24172896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early antibody therapy can induce long-lasting immunity to SHIV.
    Nishimura Y; Gautam R; Chun TW; Sadjadpour R; Foulds KE; Shingai M; Klein F; Gazumyan A; Golijanin J; Donaldson M; Donau OK; Plishka RJ; Buckler-White A; Seaman MS; Lifson JD; Koup RA; Fauci AS; Nussenzweig MC; Martin MA
    Nature; 2017 Mar; 543(7646):559-563. PubMed ID: 28289286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.
    Caskey M; Schoofs T; Gruell H; Settler A; Karagounis T; Kreider EF; Murrell B; Pfeifer N; Nogueira L; Oliveira TY; Learn GH; Cohen YZ; Lehmann C; Gillor D; Shimeliovich I; Unson-O'Brien C; Weiland D; Robles A; Kümmerle T; Wyen C; Levin R; Witmer-Pack M; Eren K; Ignacio C; Kiss S; West AP; Mouquet H; Zingman BS; Gulick RM; Keler T; Bjorkman PJ; Seaman MS; Hahn BH; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC; Klein F
    Nat Med; 2017 Feb; 23(2):185-191. PubMed ID: 28092665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
    Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.
    Klein F; Halper-Stromberg A; Horwitz JA; Gruell H; Scheid JF; Bournazos S; Mouquet H; Spatz LA; Diskin R; Abadir A; Zang T; Dorner M; Billerbeck E; Labitt RN; Gaebler C; Marcovecchio P; Incesu RB; Eisenreich TR; Bieniasz PD; Seaman MS; Bjorkman PJ; Ravetch JV; Ploss A; Nussenzweig MC
    Nature; 2012 Dec; 492(7427):118-22. PubMed ID: 23103874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.
    Cohen YZ; Butler AL; Millard K; Witmer-Pack M; Levin R; Unson-O'Brien C; Patel R; Shimeliovich I; Lorenzi JCC; Horowitz J; Walsh SR; Lin S; Weiner JA; Tse A; Sato A; Bennett C; Mayer B; Seaton KE; Yates NL; Baden LR; deCamp AC; Ackerman ME; Seaman MS; Tomaras GD; Nussenzweig MC; Caskey M
    PLoS One; 2019; 14(8):e0219142. PubMed ID: 31393868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls.
    McMahon JH; Zerbato JM; Lau JSY; Lange JL; Roche M; Tumpach C; Dantanarayana A; Rhodes A; Chang J; Rasmussen TA; Mackenzie CA; Alt K; Hagenauer M; Roney J; O'Bryan J; Carey A; McIntyre R; Beech P; O'Keefe GJ; Wichmann CW; Scott FE; Guo N; Lee ST; Liu Z; Caskey M; Nussenzweig MC; Donnelly PS; Egan G; Hagemeyer CE; Scott AM; Lewin SR
    EBioMedicine; 2021 Mar; 65():103252. PubMed ID: 33640794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
    Rai MA; Blazkova J; Justement JS; Shi V; Kennedy BD; Manning MR; McLaughlin M; Sneller MC; Pau AK; Moir S; Chun TW
    EBioMedicine; 2024 Jun; 104():105151. PubMed ID: 38728839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges.
    Liu ZJ; Bai J; Liu FL; Zhang XY; Wang JZ
    Int Immunopharmacol; 2017 Nov; 52():44-50. PubMed ID: 28858725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
    Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
    J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1.
    Matsushita S; Yoshimura K; Ramirez KP; Pisupati J; Murakami T;
    AIDS; 2015 Feb; 29(4):453-62. PubMed ID: 25630040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.
    Pace CS; Song R; Ochsenbauer C; Andrews CD; Franco D; Yu J; Oren DA; Seaman MS; Ho DD
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13540-5. PubMed ID: 23878231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
    Bar-On Y; Gruell H; Schoofs T; Pai JA; Nogueira L; Butler AL; Millard K; Lehmann C; Suárez I; Oliveira TY; Karagounis T; Cohen YZ; Wyen C; Scholten S; Handl L; Belblidia S; Dizon JP; Vehreschild JJ; Witmer-Pack M; Shimeliovich I; Jain K; Fiddike K; Seaton KE; Yates NL; Horowitz J; Gulick RM; Pfeifer N; Tomaras GD; Seaman MS; Fätkenheuer G; Caskey M; Klein F; Nussenzweig MC
    Nat Med; 2018 Nov; 24(11):1701-1707. PubMed ID: 30258217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.
    Lu CL; Murakowski DK; Bournazos S; Schoofs T; Sarkar D; Halper-Stromberg A; Horwitz JA; Nogueira L; Golijanin J; Gazumyan A; Ravetch JV; Caskey M; Chakraborty AK; Nussenzweig MC
    Science; 2016 May; 352(6288):1001-4. PubMed ID: 27199430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.